[1]
|
J. L. Beaumont, L. A. Carlson, G. R. Cooper, Z. Fejfar, D. S. Fredrickson and T. Strasser, “Classification of Hyperlipidaemias and Hyperlipoproteinaemias,” Bull World Health Organ, Vol. 43, No. 6, 1970, pp. 891-915.
|
[2]
|
D. S. Fredrickson, R. I. Levy and R. S. Lees, “Fat Transport in Lipoproteins—An Integrated Approach to Mechanisms and Disorders,” New England Journal of Medicine, Vol. 276, No. 5, 1967, pp. 273-281.
doi:10.1056/NEJM196702022760507
|
[3]
|
R. J. Havel, “Pathogenesis, Differentiation and Management of Hypertriglyceridemia,” Advances in Internal Medicine, Vol. 15, 1969, pp. 117-154.
|
[4]
|
A. D. Schachter, J. Strehlau, D. Zurakowski, et al., “Increased Nuclear Factor-KappaB and Angiotensinogen Gene Expression in Posttransplant Recurrent Focal Segmental Glomerulosclerosis,” Transplantation, Vol. 70, No. 7, 2000, pp. 1107-1110.
doi:10.1097/00007890-200010150-00021
|
[5]
|
C. C. Yu, C. W. Yang, M. S. Wu, et al., “Mycophenolatemofetil Reduces Renal Cortical Inducible Nitric Oxide Synthase mRNA Expression and Diminishes Glomerulosclerosis in MRL//pr Mice,” Journal of Laboratory and Clinical Medecine, Vol. 138, No. 1, 2001, pp. 69-77. doi:10.1067/mlc.2001.115647
|
[6]
|
F. Zheng, Q. L. Cheng, A. R. Plati, et al., “The Glomerulosclerosis of Aging in Females: Contribution of the Proinflammatorymesangial Cell Phenotype to Macrophage Infiltration,” American Journal of Pathology, Vol. 165, No. 5, 2004, pp. 1789-1798.
doi:10.1016/S0002-9440(10)63434-7
|
[7]
|
A. Yamamoto, A. Kawaguchi, M. Harada-Shiba, M. Tsushima and S. Kojima, “Apheresis Technology for Prevention and Regression of Atherosclerosis: An Overview,” Therapeutic Apheresis, Vol. 1, No. 3, 1997, pp. 233-241. doi:10.1111/j.1744-9987.1997.tb00144.x
|
[8]
|
A. Hoffmann and D. Baltimore, “Circuitry of Nuclear Factor Kappa B Signaling,” Immunological Reviews, Vol. 210, No. 4, 2006, pp. 171-86.
doi:10.1111/j.0105-2896.2006.00375.x
|
[9]
|
K. W. Walton, “Fat Transport by Lipoproteins in Health and Disease,” Journal of Atherosclerosis Research, Vol. 7, No. 5, 1967, pp. 533-536.
doi:10.1016/S0368-1319(67)80031-0
|
[10]
|
D. X. Qin, X. Zou, W. Luo, et al., “Expression of Some Neurotrophins in the Spinal Motoneurons after Cord Hemisection in Adult Rats,” Neuroscience letters, Vol. 410, No. 3, 2006, pp. 222-227.
doi:10.1016/j.neulet.2006.10.006
|
[11]
|
J. Morrissey and S. Klahr, “Transcription Factor NF-KappaB Regulation of Renal Fibrosis during Ureteral Obstruction,” Seminars in Nephrology, Vol. 18, No. 6, 1998, pp. 603-611.
|
[12]
|
L. Toma, C. S. Stancu, G. M. Botez, A. V. Sima and M. Simionescu, “Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose,” Biochemical and Biophysical Research Communications, Vol. 390, No. 3, 2009, pp. 877-882. doi:10.1016/j.bbrc.2009.10.066
|
[13]
|
S. Wahyudi and D. Sargowo, “Green Tea Polyphenols Inhibit Oxidized LDL-Induced NF-KB Activation in Human Umbilical Vein Endothelial Cells,” Acta Medica Indonesiana, Vol. 39, No. 2, 2007, pp. 66-70.
|
[14]
|
R. K. Tangirala, K. Murao and O. Quehenberger, “Regulation of Expression of the Human Monocyte Chemotactic Protein-1 Receptor (hCCR2) by Cytokines,” Journal of Biological Chemistry, Vol. 272, No. 12, 1997, pp. 8050-8056. doi:10.1074/jbc.272.12.8050
|
[15]
|
K. S. Weber, P. J. Nelson, H. J. Grone and C. Weber, “Expression of CCR2 by Endothelial Cells: Implications for MCP-1 Mediated Wound Injury Repair and in Vivo Inflammatory Activation of Endothelium,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 19, No. 9, 1999, pp. 2085-2093.
|